I read with great interest the article by Courson and colleagues titled ''Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.'' 1 In this study, the authors compared inpatient combination therapy with rifaximin and lactulose to lactulose monotherapy. The primary end point, hospital length of stay, was not significantly different between combination therapy (8 days) and monotherapy (6 days; P ¼ .9). However, a significant reduction was found with 180-day readmission rates due to recurrent hepatic encephalopathy with combination therapy (2.4%) versus monotherapy (16.2%; P ¼ .02). An important clarification regarding the rifaximin duration and indication is needed to provide the ability to extrapolate results to other institutions.
Rifaximin is approved by the Food and Drug Administration for the reduction of overt hepatic encephalopathy and has an off-label indication for the treatment of acute hepatic encephalopathy. 2,3 As noted in the study, the efficacy of rifaximin for the reduction of overt hepatic encephalopathy is well established, with limited data available for the indication of acute treatment. 4 The authors present the use of rifaximin for the offlabel indication in their study. 1 However, 42.6% of patients in the combination therapy group were discharged on rifaximin therapy. The significance of the 180-day readmission rate outcome should be evaluated in the context of rifaximin outpatient therapy for the reduction of recurrent hepatic encephalopathy episodes. Rifaximin has previously demonstrated to reduce the time to hospital readmission due to recurrent hepatic encephalopathy episodes in a 6-month time period. 4 Outpatient rifaximin use may be a significant confounder in the present study and a reason for the reduction in hospital readmissions.
The current study provides a needed increase in the body of literature for rifaximin in acute hepatic encephalopathy. Further explanation of the total rifaximin utilization in the study period outside the inpatient use would be helpful. This could allow readers to differentiate between which rifaximin treatment indication is having the true impact on readmission rates.
